Ulabs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 31-10-2024
- Paid Up Capital ₹ 0.25 M
as on 31-10-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -43.46%
(FY 2023)
- Profit -190.62%
(FY 2023)
- Ebitda -446.02%
(FY 2023)
- Net Worth -53.17%
(FY 2023)
- Total Assets -75.92%
(FY 2023)
About Ulabs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.25 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Uppal and Vijay Uppal serve as directors at the Company.
- CIN/LLPIN
U24230CH2020PTC043122
- Company No.
043122
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ulabs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Uppal  | Director | 31-Jul-2020 | Current |
| Vijay Uppal | Director | 31-Jul-2020 | Current |
Financial Performance of Ulabs.
Ulabs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 43.46% decrease. The company also saw a substantial fall in profitability, with a 190.62% decrease in profit. The company's net worth observed a substantial decline by a decrease of 53.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ulabs?
Unlock access to Ulabs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Vadsp Pharma Care Private LimitedActive 36 years 7 monthsAnand Uppal and Vijay Uppal are mutual person
Chemzin Graphics Private LimitedActive 4 years 4 monthsAnand Uppal and Vijay Uppal are mutual person
Biotrendz Medicament Private LimitedActive 4 years 10 monthsAnand Uppal and Vijay Uppal are mutual person
- Chemzin Biotox Research Institute Private LimitedActive 1 year 3 months
Anand Uppal and Vijay Uppal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ulabs?
Ulabs has a workforce of 14 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ulabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ulabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
